To learn more about this report, request sample copy
North America remains the dominant region in the global pharmacogenomics market and is estimated to hold 36.2% of the market share in 2024 due to the presence of major pharmaceutical companies and established biotechnology industry in the region. The U.S. is a hub for drug innovation and discovery activities. The presence of leading pharmaceutical companies with strong R&D capabilities allows them to invest heavily in pharmacogenomic research. Additionally, supportive regulatory environment and increasing adoption of personalized medicine approach have further boosted the market growth in the region.
The Asia Pacific region has emerged as the fastest growing market for pharmacogenomics in recent years. Rapid economic development and growing healthcare investments in countries like China and India have created conducive environment for market growth. Rising patient population and increasing burden of chronic diseases have bolstered the demand. Furthermore, improving access to healthcare along with increasing disposable incomes have augmented the demand for advanced diagnostic technologies in the region. India and China offer low-cost operations which attract global pharmaceutical players to invest in local manufacturing and clinical trials. This has provided major impetus to the regional market.
Pharmacogenomics Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients